Back to results
US 2019/0316104 A1Published application
Methods and compositions for treatment of lafora disease
AssigneeValerion Therapeutics, LLC
InventorDustin D. Armstrong
Life of this patent
Estimating the term…
Abstract
In certain embodiments, the present disclosure provides compositions and methods for treating Lafora Disease.
Claims35
A chimeric polypeptide comprising:
- (i) an alpha-amylase polypeptide, and (ii) an internalizing moiety;
- wherein the alpha-amylase polypeptide comprises the amino acid sequence of SEQ ID NO:
- 1;
- and wherein the internalizing moiety is an antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain and a light chain variable domain;
- wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:
- 2;
- and wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO:
- 3.
5 more elements
A chimeric polypeptide comprising:
- (i) an alpha-amylase polypeptide, and (ii) an internalizing moiety;
- wherein the alpha-amylase polypeptide comprises the amino acid sequence of SEQ ID NO:
- 1, but wherein the alpha-amylase polypeptide does not comprise the full-length alpha-amylase polypeptide of SEQ ID NO:
- 36;
- and wherein the internalizing moiety is an antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises a heavy chain comprising a heavy chain variable domain and a light chain comprising a light chain variable domain;
- wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:
- 2;
- and wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO:
- 3.
6 more elements
-7. (canceled)
(canceled)
(canceled)
-16. (canceled)
-23. (canceled)
-32. (canceled)
(canceled)
-42. (canceled)
(canceled)
(canceled)
(canceled)
-70. (canceled)
-74. (canceled)
Dependencies are inferred from the claim text.